SEC Filing Summary: BioSig Technologies, Inc.
Business Context and Reporting Period
This Form 8-K Current Report was filed by BioSig Technologies, Inc. (not Streamex Corp.) on February 14, 2017, covering events occurring on February 9, 2017. The filing details a material amendment to a prior Unit Purchase Agreement and the issuance of unregistered equity securities.
Key Financial Metrics and Transaction Details
- Transaction Type: Amendment to Unit Purchase Agreement and issuance of additional securities.
- Price Adjustment: The purchase price per unit and the exercise price per share for outstanding Warrants were reduced from $1.75/$2.10 to $1.50.
- Securities Issued: 12,858 shares of Common Stock and Warrants to purchase 6,429 shares of Common Stock were issued to three purchasers.
- Outstanding Warrants: As of the effective date, Warrants to purchase 38,572 shares of common stock were outstanding.
- Financial Performance: The filing text does not provide revenue, profit, cash flow, margin, debt, or liquidity figures.
Material Changes
The primary material change is the reduction of the exercise price for existing warrants and the purchase price for new units to $1.50. This adjustment was made effective February 9, 2017, altering the terms of the original agreement dated May 26, 2016.
Guidance, Risks, and Unusual Items
- Unregistered Sales: The issuance of the new shares and warrants was not registered under the Securities Act of 1933. It relied on exemptions under Section 4(a)(2) and Regulation D (Rule 506).
- Management Commentary: The filing contains no forward-looking guidance or management outlook regarding future operations.
- Risks: The filing notes that the description of the Amendment Agreement is qualified by reference to the full text filed as Exhibit 10.1.
Investor Verification Checklist
- Verify the full text of the Amendment Agreement (Exhibit 10.1) for additional covenants or conditions not summarized here.
- Confirm the identity of the three purchasers who received the unregistered securities.
- Review the company's latest 10-K or 10-Q for current financial health, as this 8-K contains no financial statements.
- Check for any subsequent filings regarding the impact of the warrant price reduction on dilution.